2023年3月29日,

馬薩諸塞州,劍橋。揭路荼療法(揭路荼),公司創造現成的、持久的血液幹細胞細胞療法,今天宣布了一項6200萬美元由Northpond融資企業,OrbiMed Advisors鸕鶿資產管理、和愛絲琳資本,參與部門資產管理,質量一般的布裏格姆,亞曆山大風險投資和其他精英投資者和個人。這使公司的資金總額1.34億美元。該公司還宣布任命雷蒙德·j·凱萊赫,醫學博士,Ph.D., Managing Director at Cormorant Asset Management, to its Board of Directors.Like bone marrow transplants, Garuda’s technology has the potential to address, and possibly cure, more than 120 diseases for a diverse population of patients with unmet medical need. Proceeds from the financing will be used to further advance the development of Garuda’s platform for generation of off-the-shelf, self-renewing blood stem cells towards the clinic as potential treatment for patients with hematological diseases. The Series B funding will also enable Garuda to continue the advancement of its proprietary HSC-derived off-the-shelf, durable immune cell program for treating patients with oncologic disorders. The funding will also further advance Garuda’s continued development of HLA-matched pluripotent stem cells greatly broadening the eligibility of patients and increasing access to blood and other cellular therapies in regenerative medicine.